Montai Therapeutics
Breakthrough small molecule medicines for chronic disease with unprecedented pathway precision and predictable discovery
63 employees · est. 2022 · Cambridge, United States
Septerna
Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.
137 employees · est. 2022 · South San Francisco, United...
1 signal in the last 90 days
Side-by-Side Comparison
| Metric | Montai Therapeutics | Septerna |
|---|---|---|
| Founded | ||
| Founded | 2022 | 2022 |
| Headquarters | ||
| Headquarters | Cambridge, United States | South San Francisco, United States |
| Employees | ||
| Employees | 63 | 137 |
| Industry | ||
| Industry | Health Care | Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series A | IPO |
| Total Funding | ||
| Total Funding | Not tracked yet | $552.60M |
| Funding Rounds | ||
| Funding Rounds | Not tracked yet | 3 |
| Services | ||
| Services | Drug Discovery and Development, AI Platform for Chemistry Analysis, Consultation and Partnerships, Research and Development of Therapies | Discovery of GPCR-targeted drug candidates, Development of oral small molecule therapies, Optimization of GPCR drug targets |
| Target Customers | ||
| Target Customers | Pharmaceutical Companies, Biotech Researchers, Healthcare Providers, Patients with Chronic Diseases | Patients with unmet medical needs, Healthcare providers, Medical researchers, Pharmaceutical investors |
| Taxonomy | ||
| Taxonomy | Small Molecule Medicines, Chronic Disease Treatment, Drug Discovery Platform, Pathway Precision, Predictable Discovery, Technology Integration, Validated Biology, Untapped Human Chemistry, Anthromolecule Medications, Digital Health Technology, Bioactivity Atlas, Human-centered Drug Development, Machine Learning In Biomedicine, Transformative Medicines, Long-term Healthcare Solutions | GPCR Medicines, Native Complex Platform, Small-molecule Drugs, Drug Discovery, Biochemical Advances, Structural Drug Development, Computational Drug Discovery, Pharmacology, High-impact Medicines, G Protein-coupled Receptors, Medicinal Chemistry, Innovation In Healthcare, Patient-centric Solutions, Bioscience Research |
| Website | ||
| Website | montai.com | septerna.com |
About Montai Therapeutics
Montai Therapeutics is emerging as a compelling player in the Health Care industry, offering innovative solutions through its flagship CONECTA platform. Founded in 2022 and headquartered in the United States, the company is actively addressing the unmet needs of chronic diseases by leveraging unmatc...
About Septerna
Septerna, founded in 2022, is a biotechnology and pharmaceutical company headquartered in the United States. With the slogan, "Bringing a new era of GPCR medicines to patients with its Native Complex Platform™," the company is pioneering innovations in the GPCR landscape. Septerna aims to transform...
We will tell you when either one moves
BounceWatch watches Montai Therapeutics and Septerna for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Montai Therapeutics and Septerna — by email.
Frequently Asked Questions
Compare Montai Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Montai Therapeutics on 26 Nov 2025, and Septerna on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
